<DOC>
	<DOCNO>NCT00478049</DOCNO>
	<brief_summary>This randomize , open-label , parallel group , phase III , multicenter , regional study . The total number patient expect exposed study procedure approximately 150 patient recruit investigational site throughout Asia Pacific region expertise treat patient NSCLC .</brief_summary>
	<brief_title>Iressa Second Line Therapy Advanced NSCLC-Asia</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell bronchogenic carcinoma : adenocarcinoma ( include bronchoalveolar ) , squamous cell carcinoma , large cell carcinoma mixed ( adenocarcinoma squamous ) undifferentiated carcinoma . WHO Performance status 02 NSCLC locally advance ( Stage IIIB ) metastatic ( stage IV ) disease , amenable curative surgery radiotherapy Life expectancy 12 week . ALT/AST : &gt; 2.5x ULRR demonstrable liver metastasis great 5 x ULRR presence liver . Inadequate bone marrow function ; Absolute neutrophil count : &lt; 1.5 x 109/L , Platelets : &lt; 100 x 109/L Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma skin cervical cancer situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>